Karyopharm Therapeutics Inc. is focusing on the potential of selinexor in multiple myeloma and diffuse large B-cell lymphoma following the drug's failure in the Phase II SOPRA study in relapsed/refractory acute myeloid leukemia, which, if it had been successful, could have paved the way for accelerated approval.
The company announced March 2 that the SOPRA study was being terminated early on the advice of a data safety...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)